Capability
Small Molecule API CDMOs
Compare CDMOs specializing in small molecule API synthesis from route scouting through commercial manufacturing. Filter by chemistry capabilities, scale, and regulatory approvals.
516 companies listed
For a small molecule API, the synthetic route is the program. A CDMO's process chemists decide how you get from raw materials to drug substance: how many steps, what yield, and which impurities you'll spend the next two years explaining to regulators. Route scouting and development are where a strong API partner earns its fee. Crystallization is the part buyers underestimate. It controls polymorphic form and particle size, and a polymorph surprise during scale-up has delayed more filings than most people admit. So probe the chemistry. Have they run your reaction types (hydrogenation, cryogenic steps, flow chemistry) at kilo-lab through metric-ton scale? Is the API high-potency, needing OEB4/5 containment? Do they have ICH Q11 filings and a defensible regulatory starting material strategy? 516 CDMOs here list small molecule API synthesis. Compare them on chemistry, scale, and regulatory experience.
About Small Molecule API Manufacturing
Active Pharmaceutical Ingredient (API) manufacturing is the chemical synthesis of the drug substance itself. For small molecules, this involves multi-step organic chemistry from raw materials to the final API, requiring expertise in reaction chemistry, purification, crystallization, and process optimization.
Process chemistry determines project success. A strong CDMO identifies the most efficient synthetic route, optimizes reaction conditions for yield and purity, and develops a process that scales reliably from gram to metric ton quantities. Crystallization expertise is particularly critical for controlling polymorphic form and particle size distribution.
Companies (516)
Grupo Ferrer Internacional, S.A. (Ferrer)
Spain
Grupo Ferrer Internacional (Ferrer) is a Spanish pharmaceutical company with certified production plants in Spain and the United States that manufactures chemical substances, APIs, and finished pharmaceutical products both for its own portfolio and for third parties under contract. The company's FDA registration is for API manufacture and analysis, and its website explicitly states it manufactures for third parties.
Small Molecule APISmall Molecule Drug ProductFormulation Development
Hanmi Pharm. Co. Ltd
South Korea
Hanmi Pharmaceutical is a major South Korean pharmaceutical company providing comprehensive CDMO services across the entire pharmaceutical lifecycle. The company operates through Paltan Smart Plant (producing 6+ billion chemical drug tablets annually), Pyeongtaek Bioplant (FDA-approved biopharmaceutical manufacturing with 12,500L bioreactors), and Hanmi Fine Chemical (API and raw materials including mRNA cap analogs, NTP, and lipids). Hanmi has partnerships with global pharma companies including Lilly, Roche, and Sanofi.
Frequently Asked Questions
What is the difference between API and drug product?+
API (Active Pharmaceutical Ingredient) is the chemical compound that provides the therapeutic effect. Drug product is the final dosage form (tablet, capsule, injectable) that patients use. API manufacturing involves chemical synthesis; drug product manufacturing involves formulation and filling. Some CDMOs do both; many specialize in one.
How do you evaluate an API CDMO's chemistry capabilities?+
Check their experience with your reaction types (hydrogenation, cryogenic chemistry, Grignard reactions, flow chemistry). Review their equipment (reactors from lab to multi-thousand-liter scale, high-pressure capability, continuous processing). Ask about their analytical support (in-process controls, impurity profiling, polymorph screening). Experience with ICH Q11 regulatory filings demonstrates maturity.
Need help finding the right CDMO?
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.
